InvestorsHub Logo
Followers 13
Posts 865
Boards Moderated 0
Alias Born 02/17/2017

Re: None

Tuesday, 02/21/2017 2:34:22 PM

Tuesday, February 21, 2017 2:34:22 PM

Post# of 232171
First post here, have enjoyed following the discussion though. Saw this in the news today:

http://www.fiercebiotech.com/biotech/sarepta-sells-exondys-51-prv-for-125m-aims-to-use-cash-for-duchenne-r-d

Anyone have any insight as to whether HIV may qualify through some loophole as a rare pediatric disease? I'm not sure GILD has anything else in their pipeline that may fit the bill, and would potentially reduce the cost/time to market for PRO 140 if they were to buy out CYDY. Seems like an interesting purchase for GILD if they don't have a drug acquisition in mind.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News